Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Deng, Ting ^a   Zhang, Le ^a   Liu, Xiao Jian ^b   Xu, Jian Ming ^c   Bai, Yu Xian ^d   Wang, Yan ^c   Han, Yu ^d   Li, Yu Hong ^e   Ba, Yi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Bevacizumab; FOLFIRI; Metastatic colorectal cancer; Second line therapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

ABNORMAL SENSATION; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHINESE; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; GINGIVA BLEEDING; HEMORRHOID; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING; YOUNG ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; KAPLAN MEIER METHOD; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; YOUNG ADULT;

MLCS; MLOWN;

EID: 84886377012     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0752-z     Document Type: Article

References (17)

1. Wan DS. Epidemiologic trend of and strategies for colorectal cancer. Ai Zheng. 2009;28:897-902.
2. Zhang S-w, Chen W-q, Kong L-z, et al. An analysis of cancer incidence and mortality from 30 cancer registries in China, 1998-2002. J Bull Chin Cancer. 2006;7:430-48.
3. Rong-shou Z, Si-wei Z, Liang-you W. Report of incidence and mortality from China cancer registries in 2008. Chin Cancer. 2012;1:002.
4. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502-8.
5. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779-86. (Pubitemid 350086481)
6. Pectasides D, Papaxoinis G, Kalogeras KT, et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a hellenic cooperative oncology group phase III trial with collateral biomarker analysis. BMC cancer. 2012;12:271.
7. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol. 2007;25:1539-44. (Pubitemid 46733080)
8. Guan ZZ, Xu JM, Luo RC, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J cancer. 2011;30:682-9.
9. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-37. (Pubitemid 41095086)
10. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311-9.
11. Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11:853-60.
12. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21:807-14. (Pubitemid 46606439)
13. Bennouna J, Borg C, Delord JP, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer. 2012;11:38-44.
14. Moriwaki T, Bando H, Takashima A, et al. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Med Oncol. 2012;29:2842-8.
15. Suenaga M, Matsusaka S, Ueno M, et al. Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. Surg Today. 2011;41:1067-74.
16. Horita Y, Yamada Y, Kato K, et al. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. Int J Clin Oncol. 2012;17:604-9.
17. Odabas H, Ozdemir N, Isik M, et al. Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment. J BUON. 2011;16:460-3.